Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FTC files for injunction against Airborne copycat

This article was originally published in The Tan Sheet

Executive Summary

The Federal Trade Commission requests a permanent injunction against supplement firm Improvita Health Products for "engaging in deceptive acts or practices in connection with the advertising, marketing, and sale of the Germ Defense line of products, which are purported to prevent, treat, or cure cold and flu," between 2005 and 2008, according to a complaint filed April 15 in the U.S. District Court for the Northern District of Ohio. FTC alleges the Cleveland-based firm's products "expressly or by implication" make certain unsubstantiated prevention and treatment claims. In its advertising the firm likens the products to Airborne, which also faced FTC scrutiny for making unsubstantiated claims (1"The Tan Sheet" Aug. 18, 2008, p. 8)

You may also be interested in...

FTC Settlement Looks To Ground Airborne Claims

Under a settlement with the Federal Trade Commission announced Aug. 14, the maker of Airborne dietary supplement products must cease unsubstantiated health-related claims and contribute up to $6.5 million to an existing consumer redress fund

Moderna Stands Alone With Single-Antigen Approach To COVID-19 Vaccine

Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.

Kansas City TCM Firm Persists With COVID-19 Claims Following US Regulators' Warning

Latest warnings also include second and third businesses in US cannabidiol and hemp sector found making unlawful claims for treating and preventing COVID-19. Four of five firms warned apparently responded by removing violative claims from websites and social media posts.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts